Knowledge graph · Drug
Hydroxyurea
small molecule
- Identifier
- CI-DRUG-00000671
- Entity page
- /drug/hydroxyurea ↗
- Edges
- 169
- Neighbours
- 28 cancers3 genes10 trials13 approvals
- Drawn
- 54 of 54 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,149Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Hydroxyurea approved for …APPROVED_FORderived13 of 13 | ||||||||
| → approved for | FDA · US · 2024XROMI is indicated to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age and older with sickle cell anemia with recurrent moderate to severe painful crises. XROMI is an antimetabolite indicated to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age and older with sickle cell anemia with recurrent moderate to severe painful crises. (1) FDA (US) · approved · 2024-12-23 · XROMI is indicated to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months… | — | approved | not mapped | 1 | Regulatory | openfda | open ↗ |